You searched for "data"
SIU (Société Internationale d'Urologie) 2025 Trainee Scholarship: An essential part of the SIU mission
SIU Congresses are the perfect opportunity to expand your knowledge and learn from world-renowned experts. To facilitate the education and training of urologists, SIU offers a merit-based scholarship for select residents / fellows from countries the World Bank classifies as...Medical Protection: Expertise, advocacy, and support when it matters most
The world’s leading medical defence organisation providing long-term protection against the potentially ruinous costs of litigation, as well as the other professional challenges that healthcare professionals might face during the course of their career. As a doctor your work is...From Peyronie to Foley: the backstories behind the urology legends
Eponyms play a significant role in the field of urology, serving as a bridge between historical medical discoveries and modern clinical practice. For urology trainees, understanding these eponyms is more than just memorising names; it enriches our grasp of key...
Multiparametric MRI with targeted-only biopsy – a new standard?
In this issue of European Urology, Kasivisvanathan et al. present a meta-analysis of two randomised trials comparing prebiopsy MRI with targeted biopsy (TBx) alone versus standard transrectal ultrasound-guided biopsy (TRUS-Bx) in biopsy-naïve men at risk of prostate cancer. Their findings...Prostate Scotland appoints digital technology leader Peter Proud as new trustee
Prostate Scotland has appointed Peter Proud, Founder and CEO of Edinburgh-based digital technology company Forrit, to its Board of Trustees. Bringing more than 30 years of experience in digital transformation, data, and AI-driven innovation, Peter will support the charity’s work...Action Bladder Cancer UK offers nursing grants for projects supporting bladder cancer
Action Bladder Cancer UK (ABC UK) is inviting specialist urology and cancer nurses to apply for funding to deliver nurse-led projects that improve bladder cancer care, patient experience and treatment pathways. The ABC UK Nursing Grants Programme offers grants of...
Boosting the immune response to Bacillus Calmette-Guérin
In this issue of European Urology, Buisan et al. report early clinical and immunological outcomes of subcutaneous priming with the non-live mycobacterium tuberculosis RUTI vaccine prior to intravesical Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer (NMIBC). The phase...
The emerging role of artificial intelligence in endourology
In an editorial written by Miernik, the growing role of artificial intelligence (AI) in urology, particularly in endourology, is critically appraised, with a focus on a novel study by Lu et al. published in this issue of BJUI. Ureteroscopy with...Evelina Paediatric Urodynamics Course 2025
This two day face to face course will start by covering normal childhood bladder and bowel anatomy and function along with an outline of Bladder Bowel dysfunction (BBD). The bulk of the course will cover urodynamic assessment of BBD both with non-invasive strategies such as Diaries, Uroflowmetry (together with use of EMG) and ultrasound scanning, and invasive urodynamics to include videourodynamics and ambulatory urodynamics. Practical demonstration along with work-shop scenarios will be provided along with case studies. We will not concentrate much on treatment but will provide demonstration of superficial neuromodulation such as TENS and the principles/practice of Biofeedback treatment.Bladder Health UK (BHUK) Trustee recruitment: strengthening governance and strategic leadership
Bladder Health UK (BHUK) is seeking new Trustees to enhance our governance, strengthen oversight and support the charity’s continued growth as a national leader in bladder health. For over 30 years, BHUK has delivered trusted patient information, a national helpline,...
PARP inhibitors and prostate cancer
The discovery that BRCA1/2-deficient tumour cells are highly sensitive to poly-ADP ribose polymerase (PARP) inhibitors (PARPi) established the foundation of synthetic lethality in metastatic castration-resistant prostate cancer (mCRPC). The TOPARP-A trial confirmed clinical benefit, with PARPi activity largely restricted to...
